UY34896A - Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina - Google Patents

Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina

Info

Publication number
UY34896A
UY34896A UY0001034896A UY34896A UY34896A UY 34896 A UY34896 A UY 34896A UY 0001034896 A UY0001034896 A UY 0001034896A UY 34896 A UY34896 A UY 34896A UY 34896 A UY34896 A UY 34896A
Authority
UY
Uruguay
Prior art keywords
laquinimod
fampridine
treatment
combination
subject
Prior art date
Application number
UY0001034896A
Other languages
English (en)
Inventor
Kaye Joel
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34896A publication Critical patent/UY34896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Esta invención proporciona 1) un método de tratamiento de un sujeto aquejado de esclerosis múltiple o la presentación de un síndrome clínicamente aislado que comprende administración al sujeto fampr idina como una terapia complementaria a o en comb inación con laquinimod; 2) un paquete o una composición farmacéutica que comprende laquinimod y fam pridina para uso en el tratamiento de dicho sujeto; 3) fampridina para su uso como complemento de la terapia o en combinación con laquinimod en el t ratamiento de dicho sujeto, y 4) uso de laquinimod y fampridina en la preparación de una combinació n para el tratamiento de dicho sujeto
UY0001034896A 2012-07-12 2013-07-09 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina UY34896A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12

Publications (1)

Publication Number Publication Date
UY34896A true UY34896A (es) 2014-02-28

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034896A UY34896A (es) 2012-07-12 2013-07-09 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina

Country Status (16)

Country Link
US (2) US20140017226A1 (es)
EP (1) EP2872217A4 (es)
JP (1) JP2015522077A (es)
KR (1) KR20150038072A (es)
CN (1) CN104582793A (es)
AR (1) AR091724A1 (es)
AU (1) AU2013290181A1 (es)
BR (1) BR112015000616A2 (es)
CA (1) CA2873229A1 (es)
EA (1) EA201590191A1 (es)
HK (1) HK1209672A1 (es)
IL (1) IL236230A0 (es)
MX (1) MX2015000485A (es)
TW (1) TW201408300A (es)
UY (1) UY34896A (es)
WO (1) WO2014011827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CA2736381A1 (en) * 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
US8889627B2 (en) * 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
AR091724A1 (es) 2015-02-25
US20160235735A1 (en) 2016-08-18
CA2873229A1 (en) 2014-01-16
KR20150038072A (ko) 2015-04-08
EP2872217A1 (en) 2015-05-20
MX2015000485A (es) 2015-04-08
BR112015000616A2 (pt) 2017-06-27
TW201408300A (zh) 2014-03-01
EA201590191A1 (ru) 2015-06-30
JP2015522077A (ja) 2015-08-03
AU2013290181A1 (en) 2015-02-26
IL236230A0 (en) 2015-01-29
US20140017226A1 (en) 2014-01-16
HK1209672A1 (en) 2016-04-08
CN104582793A (zh) 2015-04-29
WO2014011827A1 (en) 2014-01-16
EP2872217A4 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
IN2014MN00333A (es)
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
GB201209609D0 (en) New compounds
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
WO2013038200A3 (en) Neurodevelopmental disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
IN2013MU02370A (es)
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
PL397785A1 (pl) Kompozycja i preparat zawierajace tioproline i ergotioneine, zastosowanie tioproliny i ergotioneiny oraz sposób ochrony skóry przed procesem starzenia zewnatrzpochodnego

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528